Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 351 to 375 of 881

TitleReference numberPublishedLast updated
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
Empagliflozin for treating chronic heart failure with reduced ejection fractionTA773
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)TA774
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA776
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA777
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuriaTA778
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Fremanezumab for preventing migraineTA764
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA765
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Ponesimod for treating relapsing–remitting multiple sclerosisTA767
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA768
Palforzia for treating peanut allergy in children and young peopleTA769
Sodium zirconium cyclosilicate for treating hyperkalaemiaTA599
Cabotegravir with rilpivirine for treating HIV-1TA757
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsyTA758
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTA754
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Dupilumab for treating severe asthma with type 2 inflammationTA751
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disordersTA748
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)TA749

Results per page

  1. 10
  2. 25
  3. 50
  4. All